Autopsy report · NCT04239014

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

“Sponsor made the decision to terminate the DUETTE study based on the interim analysis of the VIOLETTE study (NCT03330847) investigating the combination of ceralasertib and Olaparib, where study closure was recommended due to insufficient efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

AstraZeneca

Sponsor type

Industry

Conditions

Ovarian Cancer

Interventions

Olaparib; Ceralasertib; Placebo to match olaparib

Participants

0

Sites

26

Countries

Canada, Italy, Spain, United States

Trials that died the same way

• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
  “The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522)” (66% match in meaning)
• Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
  “The trial is closing due to findings from a related study, prompting the sponsor to discontinue development and end this study.” (64% match in meaning)
• Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
  “The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.” (63% match in meaning)
• A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
  “The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.” (63% match in meaning)
• Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma
  “The lack of adequate funding has made it impossible to continue with the clinical study As this study was not initiated, no subject was included and no data was collected,thus no result can be obtained SPONSOR\_DECISION End of trial date:15 Oct 2025” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.